The use of the Registered Reports format for publication of randomized clinical trials: a cross-sectional study

Norah Anthony,* Public Health Doctor[1] Antoine Tisseaux, Public Health Resident[1], Florian Naudet, Professor of Therapeutics[2, 3*]

[1]: National Institute of Health and Medical Research (INSERM), CIC 1410 Saint Pierre, Reunion Island
[2]: Univ Rennes, CHU Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, CIC 1414 [(Centre d'Investigation Clinique de Rennes)], F-35000 Rennes, France
[3]: Institut Universitaire de France (IUF)

* : corresponding author ; mail a-norah@hotmail.fr
ORCID
Norah Anthony: 0000-0002-2738-0336
Antoine Tisseaux: 0000-0001-6159-7419
Florian Naudet: 0000-0003-3760-3801

What is new ?

- The use of registered report format for randomized controlled trials is still marginal and few journals practice it.
- Randomized controlled trials identified as registered reports did not necessarily respect basic features of this format and thus common bias may persist.
- To improve research trustworthiness, more efforts need to be done by Journals, trials funders etc. regarding implementation of this format for randomized controlled trials.

Abstract

Objective: Registered Reports is a new publication format that aims to strengthen the trustworthiness of research papers by reducing issues such as publication bias and outcome switching. It involves a peer review of the protocol before the start of the study followed by an in-principle acceptance by the journal before the study results are known. Because of the coherence of the requirements of this format with the confirmatory nature of randomized controlled trials (RCTs), we aimed to identify and describe RCTs published as Registered Reports.

Design: Cross-sectional study

Setting: PubMed/Medline and a Zotero library compiled by the Center for Open Science

Eligibility criteria: Publications identified as Registered Reports reporting results of RCTs

Main outcome measures: The primary outcome was the proportion of reports that received an in-principle acceptance and/or published a protocol before inclusion of the first patient. A secondary outcome concerned information collected on changes in the primary outcome (in relation to the protocol).

Results: A total of 93 RCT publications identified as Registered Reports were included. All but one were published in the same journal group. The date of the in-principle acceptance was never documented. For 8/93 reports (8.6%), a protocol was published in a journal before inclusion of the first patient. Missing dates prevented any checks for a further 6/93 reports. The remaining 79/93 (84.9 %) had a protocol published after the date of inclusion of the first patient. A change in the primary outcome in relation to the protocol was noted in 40/93 (44%) of these publications and 3/40 (33%) mentioned this change.

Conclusions: Not only is therapeutic research lagging behind with regard to the implementation of registered reports, but its implementation to date has been far removed from the very idea of this new publication. format. Journals need to implement this new publication format correctly in order to increase trustworthiness of therapeutic research.

Protocol registration: https://osf.io/zf53p/

Introduction

Clinical trial results shape clinical practice guidelines and support decisions that affect millions of people's health. According to clinicaltrials.gov, "in a clinical trial, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants' behavior, such as diet." Randomization is a method used to randomly assign participants to the arms of the clinical study and is key to ensure the initial comparability of the groups. Following the Thalidomide crisis in 1962 (1), randomization became a gold standard for clinical trials in order to maximize their internal validity. Because their results must be trustworthy and resist the considerable financial and ideological conflicts of interest inherent in the evaluation of therapeutics, randomized controlled trials (RCTs) have long been at the forefront of efforts to ensure transparency and reproducibility. In 2005, to enhance transparency, the International Committee of Medical Journal Editors (ICMJE) mandated registration of RCT before inclusion of the first patient (2). However, and despite these efforts, many issues remain. Many RCTs results remain unpublished, especially when conclusions are "negative" (3). When published, RCTs results are frequently reported with a certain amount of selective reporting and spin (4). Initiatives promoting RCTs data-sharing are insufficient (5). In addition, RCTs all too often ask the wrong question, e.g. by relying on the wrong comparator, and/or they implement inadequate methods, e.g. the use of non-informative surrogate outcomes or have a lack of adequate power (6). All these problems hamper reproducibility and reduce the value of therapeutic research. Similar concerns have been described in many scientific disciplines such as psychology (7) and cancer biology (8) suggesting the existence of a reproducibility crisis in science (9).

A new publication format - Registered Reports - was created to address these systemic flaws by increasing transparency and relying on a strict hypothetico-deductive model of scientific method (10,11). In a Registered Report, the study protocol - including theory, hypotheses, detailed methods, and analysis plan - is submitted directly to a journal, and peer-review of this material - i.e. stage 1 peer review - occurs before the research is underway. Stage 1 peer review appraises both the importance of the research question and the quality of methodology prior to data collection (12–14). Following the stage 1 peer review, high quality protocols exploring relevant research questions receive an in-principle acceptance for publication in the journal, conditional on the successful completion of the study in accordance with the protocol. Provisional acceptance is therefore given without knowledge of the research results, or whether or not the study hypothesis is verified. Following an in-principle acceptance, the investigators can register their protocol and start the research. Once the research is completed, stage 2 peer review checks compliance with the protocol

and the accuracy of conclusions in view of the evidence. Figure 1 (adapted from the figure proposed by the Center For Open Science (12)) details the whole process of Registered report. This approach is expected to promote high quality of methods and to reduce issues such as publication bias. In addition, if qualitative, stage 1 peer-review may fix pre-emptively certain issues regarding design and should improve robustness of the methods. Stage 2 peer review ensures the compliance with the methodology validated in stage 1 and leads to the publication of the study whatever the results are. Such an approach is expected to limit publication bias and selective outcome reporting. Register reports also presents the advantage of pre-emptively fixing the terms of important issues such as data-sharing which should indeed be addressed before inclusion of the first patient in order to make sure that trial participants are adequately informed. This process is therefore quite different from the publication of a protocol. If publishing the protocol is generally considered as a good practice in terms of research transparency, it does not prevent the possibility of publication and selective outcome reporting bias in the final report. In addition, unlike the registered report format, publication of the protocol is often done after the study has started and it does not allow for fixing any issue regarding the research question and design based on the reviewer's comments. Furthermore, in some case, there is no specific peer review by the journal for those protocols, e.g. at BMJ Open, acceptance is offered providing the study 1/ was funded by a funding body performing peer review and 2/ get an authorization by an appropriate Institutional review board (15). Finally, it is also worth noting that the use of registered reports in journals is generally associated with other open science practices (16).

To date, more than 300 scientific journals, mainly, but not only, from the field of psychology (11), have adopted the Registered Report format. These journals include PLOS Biology, BMJ Open Science and Nature Human Behavior. Despite the adequate fit between the requirements of the registered format and the confirmatory nature of RCTs (14), few medical journals have implemented Registered Reports. BMC Medicine launched the first Registered Report format for RCTs in 2017 (14). The mega-journal PLOS ONE which occasionally publishes RCTs has adopted the Registered Report format(17). The specialist journals affiliated to the Journal of Medical Internet Research (JMIR) also accept Registered Reports and assign them an International Registered Report Identifier (IRRID) number (18). Our objective was to identify and describe features of randomized controlled trials published as Registered Reports.

Method

The methods of this cross-sectional study were specified in advance. They were documented in a protocol registered with the Open Science Framework on 17th December 2021 (https://osf.io/zf53p/).

Eligibility criteria

We surveyed RCTs published as final reports of a Registered Report. Registered Report protocols (i.e. stage 1 registered reports) were not included.

Search strategy and study selection

The search of these Registered Reports used the Medline database with the following search string: ““registered report” or "IRRID”. In addition, we searched a list of published Registered Reports in a Zotero library compiled by the Center for Open Science https://bit.ly/2pJRYz3. Database searches were performed on 17th December 2021.

All references identified were first automatically screened using R, excluding references where the title included the word "protocol" and/or did not include the character string "random". This procedure was validated on 100 randomly-sampled references, retrieving 100 % accuracy before being implemented (details of the validation procedure are shown in **Web Appendix 1**). All remaining references were then manually selected by two independent reviewers (NA and AT). Any disagreement was resolved by consensus with FN.

Outcomes

Primary outcome

The primary outcome was the proportion of RCTs identified as a Registered Report that had received an in-principle acceptance and/or had published a protocol before inclusion of the first patient.

Additional information was collected on i) the protocol (protocol availability, date of the time-stamped protocol, date of the protocol submission, date of protocol acceptance, date of protocol publication in a journal and publication of the protocol in the same journal or journal group), ii) the primary outcome used in the Registered Report (change in the primary outcome and in case of a change, mention of the change in the Registered Report), iii) the secondary outcomes used in the Registered Report (change in the secondary outcomes and in case of a change, mention of the change in the Registered Report), iv) result of the study for its primary outcome (positive or negative), v) sample size, vi) power to detect effect sizes of respectively 0.3, 0.5 and 0.8 (based on sample size in each arm of the trial), vii) citation rate, viii) Altmetric attention score and ix) characteristics of the Registered Report (journal, journal impact factor and topic).

Data extraction

Two authors (NA and AT) independently extracted the data from the studies included. Disagreements were resolved by consensus or in consultation with a third reviewer (FN). Data extraction for the number of citations and the Altmetric attention score was performed on the 27th April 2022.

Statistical methods

A descriptive analysis was performed using the following: medians (and range) for quantitative variables, numbers and percentages for qualitative variables. Statistical analyses were performed using R version 4.0.3.

Deviations from the protocol or addition of elements

For the sake of simplicity, the power calculation was limited to parallel RCTs, which accounted for most of the Registered Reports. Since the date of the first inclusion of patients was only documented as month and year, we computed time lapses using months as the unit.

As during our searches, we identified several publications that, despite being identified as Registered Reports, were secondary analyses and not the report of the primary analysis of the trial (e.g. based on the pre-specified analysis of its primary outcome), we added this feature (primary/secondary analysis) as part of our outcomes and have detailed our results according to this variable.

Patient involvement

We had no established contacts with specific patient groups who might be involved in this project. No patients were involved in defining the research question or the outcome measures, nor were they involved in the design and implementation of the study. There are no plans to involve patients in the dissemination of results, nor will we disseminate results directly to patients.

Results

A total of 2074 references were identified from both Zotero (n=194) and Medline (n=1880). 115 references remained after deduplication and automatic screening. Of these, 22 were not identified as Registered Reports, and 93 references were eligible for inclusion because they were identified as Registered Reports and/or had an IRRID (**Figure 2**). Of the 93, 78 (83.9 %) reported results on the primary trial analysis and 15 (16.1 %) reported on a secondary analysis.

Primary outcome

The date of the in-principle acceptance was never documented in the reports included. Consequently, we relied on the date of protocol publication. We identified a protocol published in a journal before inclusion of the first patient for 8/93 reports and protocol acceptance before first

inclusion for 8/93 reports. The lack of dates prevented any checks regarding protocol publication and protocol acceptance respectively for an additional 6/93 and 14/93 Registered Reports. In other words, 79/93 (84.9 %) had a protocol published after the date of inclusion of the first patient and 71/93 (76.3%) had a protocol accepted after the first inclusion. **Figure 3** reports the results for our primary outcome in the sample of 78/93 (83.9%) Registered Reports reporting results of primary analyses. In this sample, 7/78 (9%) had a protocol published in a journal before inclusion of the first patient, 5/78 (6.4 %) had missing data and 66/78 (84.6 %) had a protocol published after the date of inclusion of the first patient. Among Registered Reports reporting on primary analyses, protocol publication ranged from a minimum of 1.4 years before to a maximum of 3 years after the inclusion of the first patient (median time lapse was 1 year); of these 78, 42 (53.8%) had their protocols published up to one year after the first inclusion. 52/78 (66.7%) were registered in a trial registry before inclusion of the first patient, 21/78 (26.9 %) were registered after inclusion of the first patient, and dates were not available for 5/78 (6.4 %).

Secondary outcomes

A protocol was available for 90/93 (97%) reports and all of these 90 protocols were published in a journal. The published protocol and its associated report were not published in the same journal group for 55 (61%) of these 90. We found no mention of OSF registration in none of those papers. A change in primary outcome compared to the protocol was noted for 40/93 (44%) of the reports, including 27/78 (35%) of the reports reporting the results of primary analyses. Among these 40 registered reports, we identified 9 that added part(s) of primary outcomes, 7 that deleted part(s) of outcomes, 1 that switched the primary outcome with a secondary outcome and 23 that modified the definition of the primary outcome (7, 3 and 13 respectively for change of period assessment, complete change of criteria and secondary analysis of RCT's data). 13/40 (33%) of the reports with a change in the primary outcome mentioned this change and these 13 reports were exclusively secondary analyses.

A change in at least one of the secondary outcomes was present in 46/87 (53%) reports of studies with secondary outcomes (absence of secondary outcomes in 5 protocols/reports) and this change was mentioned by 8/46 (17%) of them.

Table 2 details these results with a specific focus on reports reporting the results of primary analyses versus those only reporting secondary analyses. The study outcomes were considered positive, mixed and negative in respectively 49 (52.7%), 10 (10.8%) and 34 (36.6%) of the reports included. The median sample size was 239 (range 13-14 482) for the 93 reports. Over the 75 trials with a parallel design, median power (interquartile range) was 51% (26%-86%), 91% (59%-99%), 99% (94%-

100%) to detect respectively effect sizes of 0.3, 0.5 and 0.8 (**Figure 4**). 53/93 (57%) of the reports were published in the JMIR and an additional 39 (42 %) were published in a JMIR-affiliated journal, leaving only one report published in Nurse Educ Today. The median Altmetric score was 2 (0-574) and the median citation rates was 2 (0-26), for a median of 374 (206-528) days after publication. Descriptive statistics for all other outcomes are displayed in **Table 1**.

Discussion

Statement of principal findings

We found 93 publications identified as Registered Reports with a registered report identification number and reporting the results of RCTs. Most of these reports were published in the JMIR or its companion journals. None of the trials included was from PLOS One. To date, BMC Medicine has only published 3 Registered Reports (19–21), none concerned a RCT.

None of the reports identified mentioned a date of in-principal acceptance. Instead of being typical Registered Reports, these publications were rather RCTs with a published protocol, this protocol being generally published or even formally accepted by peer-review after inclusion of the first patient. Indeed, protocols were generally submitted after the start of the study. This goes against the very principle of Registered Reports. Indeed, Registered Reports are not only a tool that can fix selective outcome reporting but also a means to enhance a given trial methodology, providing a good quality peer review. When a study is started it is already too late to fix critical points regarding methodology. Therefore, we can argue that such a posteriori submission/acceptance of protocols is a major deviation of the original concept of Register Reports. Furthermore, these protocols were often published in journals that were different from the journal publishing the final report. Of course, having a published protocol is surely a good thing for a RCT, as it should be associated with greater quality (22). For instance, the trials included in our survey may be larger than the prototypal RCT published in the field of biomedicine - as illustrated by a recent example in RCTs on interventions for mood, anxiety, and psychotic disorders (23) - with a majority sufficiently powered to detect effect sizes larger than 0.5. However, having a published protocol is not sufficient for being a Registered Report, especially when the protocol is published in a journal that is independent from the journal accepting the final report. In this case despite having an IRRID, these final reports can hardly be considered as a registered report and are at least in major deviation. An even greater subject of concern is that some of the trials included were registered retrospectively on a RCT registry. Some of the publications with a Registered Report identification number reported on the results of secondary analyses. For the reports of results of primary analyses, we identified frequent changes in the

primary outcomes between the published protocol and the final publication. Few of those changes were explicitly discussed in the reports.

Strengths and weaknesses of this study

Our focus on RCTs makes sense because of the importance these studies have in evidence-based medicine. In addition, proponents of Registered Reports have explicitly proposed that this format should be mandatory for RCTs because of the confirmatory nature of these trials (14). However, care should be taken to not generalize our results to other types of study, other journals and indeed to other fields. We found a very selected sample of trials, derived from a specific journal group - JMIR focuses mainly on digital interventions - with its own policy. Measures of impact and attention - such as citations and attention score - suggest that the trials included had modest impact/media coverage.

Identifying Registered Reports is a difficult task. It is possible that our literature searches missed some references, as it has been previously noted that a substantial number of published final reports did not clearly identify themselves as Registered Reports (24). In contrast, the use of IRRID may have more easily captured all JMIR publications. During the peer review process, we also used terms such as "registered replication report*" and "preregistered report*" and found no additional reference.

A nice perspective or “mise en abîme” would have been to publish this study as a Registered Report, but on this occasion, we refrained because it is more a descriptive survey that was not based on hypothesis testing. To ensure transparency and reproducibility, the study was registered before data collection and all data, including all references included, are shared on the Open Science Framework.

Strengths and weaknesses in relation to other studies

Previous studies of Registered Reports have highlighted a number of implementation issues and have proposed to develop standards that ensure optimal implementation of this new publication format (14,24). These standards are definitely needed for Registered Reports of RCTs. Of course, there is a continuum of practices between protocol registration, publication of the protocol and indeed the Registered Report (14) and some of the practices at JMIR may be good for reproducibility purposes. Still, one should pay a very particular attention to the use of the term Registered Report or to the assignment of a registered report identification number to these studies.

If Registered Reports hold major promises in strengthening the integrity of the publication landscape, it must be acknowledged that evidence of their real impact is still preliminary. One

specific study has attempted to evaluate the quality of Registered Reports in comparison to non-Registered Report papers in psychology and neuroscience, with positive results regarding the soundness of the Registered Report methodology and overall quality (25). Another study in the psychology literature shows a lower rate of positive results in registered reports versus standard literature, suggesting a lower rate of publication bias with registered reports (26). Regarding, Registered report's impact, an ongoing study shows that registered reports may be associated with more citations, but this is preliminary data and this may be related to the originality of the format than the content of the RRs that attracts these citations (27).

Future development will require meta-research to demonstrate the beneficial impact of this format. A collaboration of journals with the Center for Open Science (COS) is underway for the conduct of a large pragmatic randomized controlled trial of Registered Reports compared with standard practice, to assess their impact on publication, research outcomes, and quality of methodology (28).

Meaning of the study: possible explanations and implications for clinicians and policy-makers

Overall, those results are compelling: not only is therapeutic research lagging behind with regard to the implementation of Registered Reports (24), but their implementation to date is far removed from the very idea of a Registered Report. With just a few exceptions, trialists interested in adopting this format cannot implement it because the journals - especially the leading general medical journals - do not provide this opportunity. Providing for Registered Reports is a first step toward a much-needed open science pathway for RCTs (6). The development of a model of this sort is not without risks for journals, and there is a need to consider some specific methodological developments relating to specific features of RCTs. For instance, usually these trials are long and carry a risk of premature trial discontinuation (22). There is also a need to coordinate the various peer reviews that a trial receives in its life-cycle, e.g. before funding, by the IRB, or by health authorities, in order to make the process the most efficient possible. Reporting guidelines such as CONSORT (29) could also evolve to fit the needs of this new publication format.

Unanswered questions and future research

Registered Reports have been developed as a means to improve research trustworthiness. We invite important RCT funders, the main health authorities and major medical journals to join forces to develop piloting systems for Registered Reports for RCTs. We cannot be satisfied with the current status quo for RCTs in which the concept of Registered Reports is almost inexistent if not subverted. In addition, when registered reports will be progressively implemented at a large scale, meta-research efforts will be needed to evaluate how different journals and disciplines implement the

format. The higher the number of RR adoptions the greater the risk for deviations from the general registered reports policies.

References

1. Naudet F, Falissard B, Boussageon R, Healy D. Has evidence-based medicine left quackery behind? Intern Emerg Med. 2015 Aug 1;10(5):631–4.

2. ICMJE | News & Editorials. Update on Trials Registration: Clinical Trial Registration: Looking Back and Moving Ahead [Internet]. [cited 2022 Jul 17]. Available from: https://www.icmje.org/news-and-editorials/clincial_trial_reg_jun2007.html

3. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008 Jan 17;358(3):252–60.

4. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010 May 26;303(20):2058–64.

5. Naudet F, Siebert M, Pellen C, Gaba J, Axfors C, Cristea I, et al. Medical journal requirements for clinical trial data sharing: Ripe for improvement. PLOS Medicine. 2021 Oct 25;18(10):e1003844.

6. Naudet F, Siebert M, Boussageon R, Cristea IA, Turner EH. An open science pathway for drug marketing authorization—Registered drug approval. PLOS Medicine. 2021 Aug 9;18(8):e1003726.

7. Estimating the reproducibility of psychological science [Internet]. [cited 2022 Jul 17]. Available from: https://www.science.org/doi/10.1126/science.aac4716

8. Errington TM, Mathur M, Soderberg CK, Denis A, Perfito N, Iorns E, et al. Investigating the replicability of preclinical cancer biology. Pasqualini R, Franco E, editors. eLife. 2021 Dec 7;10:e71601.

9. Baker M. 1,500 scientists lift the lid on reproducibility. Nature News. 2016 May 26;533(7604):452.

10. Munafò MR, Nosek BA, Bishop DVM, Button KS, Chambers CD, Percie du Sert N, et al. A manifesto for reproducible science. Nature Human Behaviour. 2017 Jan 10;1(1):0021.

11. Center for Open. Registered Reports: Peer review before results are known to align scientific values and practices [Internet]. [cited 2022 Jul 17]. Available from: https://www.cos.io/initiatives/registered-reports

12. Registered Reports [Internet]. [cited 2018 Jul 3]. Available from: https://cos.io/rr/

13. Promoting reproducibility with registered reports. Nat Hum Behav. 2017 Jan 10;1(1):1–1.

14. Chambers CD, Tzavella L. The past, present and future of Registered Reports. Nat Hum Behav. 2021 Nov 15;1–14.

15. BMJ Journals. BMJ Open [Internet]. BMJ Open. [cited 2022 Dec 20]. Available from: https://bmjopen.bmj.com/pages/authors

16. Montoya AK, Krenzer WLD, Fossum JL. Opening the Door to Registered Reports: Census of Journals Publishing Registered Reports (2013–2020). Collabra: Psychology. 2021 Jun 8;7(1):24404.

17. Registered Reports: One Year at PLOS ONE [Internet]. EveryONE. 2021 [cited 2022 Dec 18]. Available from: https://everyone.plos.org/2021/03/30/registered-reports-one-year-at-plos-one/

18. Editorial director of JMIR. What is an International Registered Report Identifier (IRRID)? [Internet]. JMIR Publications. [cited 2022 Jul 17]. Available from: https://support.jmir.org/hc/en-us/articles/360003797672-What-is-an-International-Registered-Report-Identifier-IRRID-

19. Butler J, Black C, Craig P, Dibben C, Dundas R, Hilton Boon M, et al. The long-term health effects of attending a selective school: a natural experiment. BMC Medicine. 2020 Apr 3;18(1):77.

20. Siebert M, Gaba J, Renault A, Laviolle B, Locher C, Moher D, et al. Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports. BMC Medicine. 2022 May 20;20(1):177.

21. Kappelmann N, Rein M, Fietz J, Mayberg HS, Craighead WE, Dunlop BW, et al. Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry. BMC Medicine. 2020 Jun 5;18(1):170.

22. Speich B, Gryaznov D, Busse JW, Gloy VL, Lohner S, Klatte K, et al. Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis. PLOS Medicine. 2022 Apr 27;19(4):e1003980.

23. Vries YA de, Schoevers RA, Higgins JPT, Munafò MR, Bastiaansen JA. Statistical power in clinical trials of interventions for mood, anxiety, and psychotic disorders. Psychological Medicine. 2022 May 19;1–8.

24. Hardwicke TE, Ioannidis JPA. Mapping the universe of registered reports. Nat Hum Behav. 2018 Nov;2(11):793–6.

25. Soderberg CK, Errington TM, Schiavone SR, Bottesini J, Thorn FS, Vazire S, et al. Initial evidence of research quality of registered reports compared with the standard publishing model. Nat Hum Behav. 2021 Aug;5(8):990–7.

26. Scheel AM, Schijen MRMJ, Lakens D. An Excess of Positive Results: Comparing the Standard Psychology Literature With Registered Reports. Advances in Methods and Practices in Psychological Science. 2021 Apr 1;4(2):25152459211007468.

27. Hummer L, Thorn FS, Nosek BA, Errington TM. Evaluating Registered Reports: A Naturalistic Comparative Study of Article Impact [Internet]. OSF Preprints; 2017 [cited 2022 Dec 20]. Available from: https://osf.io/5y8w7/

28. Nosek BA, Mellor DT, Errington TM, Soderberg CK, Krall T, Grasty FL, et al. NSF Science of Science Proposal: Randomized Trial of Registered Reports [Internet]. MetaArXiv; 2020 [cited 2022 Jul 18]. Available from: https://osf.io/preprints/metaarxiv/jvxab/

29. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 24;340:c332.

Competing interest

None of the authors had any conflict of interest.

FIGURES

Figure 1. Chart representing different publication process for a clinical trial and, possibly its protocol

Figure 2. Flow chart of Registered Report selection

Figure 3. Chart representing randomized controlled trial registration *(orange)*, submission of the protocol *(red)*, acceptance of the protocol *(green)*, and protocol publication *(blue)* in comparisons with date of inclusion of the first patient *(black)*

Figure 4. Power analyses

A. Density curves representing trial sample size distribution and arm sample size distribution

B. Box plot representing power values to detect three different effect sizes

WEB-APPENDIX

Web appendix 1: Validation of the procedure for Registered Report selection

TABLE

Table 1.

	All references (N=93)	Primary analyses (N= 78)	Secondary analyses (N = 15)
Journal			
J Med Internet Res *(5.428[+])*	53 (57.0%)	48 (61.5%)	5 (33.3%)
JMIR Cancer *(NA[+])*	1 (1.1%)	1 (1.3%)	0 (0.0%)
JMIR Cardio *(NA[+])*	1 (1.1%)	1 (1.3%)	0 (0.0%)
JMIR Form Res *(NA[+])*	4 (4.3%)	3 (3.8%)	1 (6.7%)
JMIR Med Educ *(NA[+])*	1 (1.1%)	1 (1.3%)	0 (0.0%)
JMIR Ment Health *(4.388[+])*	4 (4.3%)	2 (2.6%)	2 (13.3%)
JMIR Mhealth Uhealth *(4.773[+])*	23 (24.7%)	18 (23.1%)	5 (33.3%)
JMIR Pediatr Parent *(NA[+])*	3 (3.2%)	2 (2.6%)	1 (6.7%)
JMIR Public Health Surveill *(4.112[+])*	2 (2.2%)	1 (1.3%)	1 (6.7%)
Nurse Educ Today *(3.442[+])*	1 (1.1%)	1 (1.3%)	0 (0.0%)
Field			
Medicine	57 (61.3%)	49 (62.8%)	8 (53.3%)
Psychology/Psychiatry	36 (38.7%)	29 (37.2%)	7 (46.7%)
Protocol availability	90 (96.8%)	75 (96.2%)	15 (100.0%)
Protocol published in a journal	90 (96.8%)	75 (96.2%)	15 (100.0%)
Protocol in the same journal / journal group[a]	35 (38.9%)	33 (44.0%)	2 (13.3%)
RCT presented on a register	89 (95.7%)	74 (94.9%)	15 (100.0%)
Name of the register[b]			
ClinicalTrials.gov	38 (42.7%)	32 (43.2%)	6 (40.0%)
ISRCTN registry	18 (20.2%)	14 (18.9%)	4 (26.7%)
ANZCTR	11 (12.4%)	10 (13.5%)	1 (6.7%)
German Clinical Trials Registry	7 (7.9%)	6 (8.1%)	1 (6.7%)
Chinese Clinical Trial Registry	6 (6.7%)	4 (5.4%)	2 (13.3%)
Netherlands Trial Register	5 (5.6%)	5 (6.8%)	0 (0.0%)
DRKS	1 (1.1%)	1 (1.4%)	0 (0.0%)
ICTRP platform	1 (1.1%)	1 (1.4%)	0 (0.0%)
Pan African Clinical Trials Registry	1 (1.1%)	1 (1.4%)	0 (0.0%)
UMIN-CTR	1 (1.1%)	0 (0.0%)	1 (6.7%)
Parallel design	75 (80.6%)	67 (85.9%)	8 (53.3%)
Number of arms[c]			
Median (range)	2 (1-8)	2 (2-8)	2 (1-4)

[+]JIF: Journal Impact Factor in 2021

[a] 3 missing data; [b] 4 missing data; [c] 2 missing data

Table 2.

	RR reporting results of primary analyses	RR reporting results of secondary analyses	All RR
Change in the primary outcome	27 / 77 (35 %)	13 / 15 (87 %)	40 / 92 (43 %)
If yes, mention of this change	0 / 27 (0 %)	13 / 13 (100 %)	13 / 40 (32 %)
Change in the secondary outcome	40 / 72 (56 %)	6 / 14 (43 %)	46 / 86 (53 %)
If yes, mention of this change	2 / 40 (5 %)	6 / 6 (100 %)	8 / 46 (17 %)

A) Classic publication process for publishing a clinical trial



B) Classic publication process for publishing a clinical trial with a publised protocol



C) Publication process for a registered report of a clinical trial




Identification of studies via databases and registers
Identification
Records identified from*:
Pubmed (n = 1880)
Zotero library (n = 194)
Records removed *before screening*:
Duplicate records removed
(n = 3)
Screening
Records automatically screened
(n = 2071)
Records excluded
(n = 1956)
Reports sought for retrieval
(n = 115)
Reports not retrieved
(n = 0)
Reports assessed for eligibility
(n = 115)
Reports excluded:
Not a registered report (n = 22)
Included
Studies included in review
(n = 93)


Individual registered reports
Distributions
Study registration, NA=5
Submission of the protocol, NA=11
Acceptance of the protocol, NA=11
Publication of the protocol, NA=5
-4
-3
-2
-1
0
1
2
3
4
Delay with inclusion of the first patient (years)


A
Trial sample size
Arm sample size
Density
0.2
0.1
0
0.1
0.2
1
10
100
500
1000
5000
15000
Sample size


B
ES=0.8
ES=0.5
ES=0.3
0.00
0.25
0.50
0.75
1.00
Power to detect the respective effect size (ES)


ZOTERO (194)
2074 papers
PUBMED (1880)
3 duplicates
2071 papers
Random sample (100 papers)
Reviewer NA
Reviewer AT
Manual strategy
Automated strategy
Automatic part on R
Manual part
6 papers
Reasons of exclusions:
- Internal pilot study inside a RCT (ISRCTN 18020851)
- Descriptive study associated to a RCT (NCT03497871)
4 eligible papers
4 eligible papers
Manual strategy
Automated strategy
Automatic part on R
Manual part
6 papers
Reasons of exclusions:
- Internal pilot study inside a RCT (ISRCTN 18020851)
- Mixed methods (qualitative + RCT) (ISRCTN39238984)
- descriptive study associated to a RCT (NCT03497871)
3 eligible papers
3 eligible papers
INTERSTRATEGY AGREEMENT = 100%
INTERSTRATEGY AGREEMENT = 100%
4 eligible papers
3 eligible papers
Reason
- Inclusion of Mixed Methods Pilot RCT (ISRCTN39238984)
INTERRATER AGREEMENT = 99%
Reason
- No inclusion of Mixed Methods pilot RCT (ISRCTN39238984)
4 eligible papers after consensus with FN